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from the database sourced from the UK drug tariff, BNF and
MIMS (with appropriate assumptions where quantities were
unclear). RESULTS: In total, 3581 patients met the inclusion
criteria. The average dose of insulin in T2D patients within the
study was 36IU/day at 12 months. The average yearly cost was
384 for insulin alone and ancillary item cost reached 223
increasing total annual cost of insulin and equipment to 607.
CONCLUSION: Although clinically appropriate for some T2D
patients, insulin is expensive, particularly when ancillaries are
considered.This database study was a straightforward way of
identifying and analysing not only drug costs but ‘hidden’ costs
of insulin ancillaries.This analysis only takes account of insulin
and ancillary costs and does not account for visits to health care
professionals. Initiation of insulin is often accompanied by extra
visits to health care professionals, which would further increase
costs.
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OBJECTIVES: The primary objective of the INSTIGATE study is
to assess the direct costs of care for type 2 diabetes in the 6
months before and after insulin initiation. This abstract presents
data for patients enrolled in Germany and UK. METHODS:
INSTIGATE is an ongoing prospective European observational
study investigating patients with type 2 diabetes who have initi-
ated insulin during usual care. The direct costs of diabetes care
over the 6 months prior to and after insulin initiation were
calculated by collecting data on individual resource use and
assigning local unit costs. Data collected included; number of
consultations with health care professionals, details of oral anti-
diabetic medications and insulins, hospitalisations for diabetes
care or complications, and frequency of blood glucose monitor-
ing. RESULTS: Five hundred and nine patients were enrolled in
Germany and UK, and 6 month follow-up data was collected
from 457 patients. In Germany the median costs per patient for
diabetes care in the 6 months prior to and after insulin initiation
were 406€ and 893€ respectively. In the UK the median costs per
patient for diabetes care in the 6 months prior to and after insulin
initiation were 596€ and 707€ respectively (2006 costs). CON-
CLUSION: For German and UK patients included in this study
the median cost of care for diabetes in the 6 months following
insulin initiation is higher than in the 6 months prior to insulin
initiation. Differences in types of resource use pre and post
insulin initiation have been observed and further analysis is
underway to investigate how these differences, and the cost of
insulin, are impacting costs of care. Outcomes following insulin
initiation will also be investigated.
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OBJECTIVES: In Spain there are several pharmaceutical prod-
ucts for the treatment of type 2 diabetes mellitus (DM2), with
different proﬁles which implies alternative patterns of adminis-
tration. A comparative study comparing annual costs linked to
the treatment with Glargine insulin (GI) and Detemir insulin (DI)
has been performed with the Spanish National Health System
perspective. METHODS: Clinical data related with each treat-
ment derives, mainly, from a study performed by Rosenstock
et.al (2006): a 52-week open-label, parallel, multinational trial,
which compares efﬁcacy and safety of GI and DI. This trial has
shown that patients treated with GI required less dairy dose of
insulin and suffer from less severe hypoglycaemia than those
patients treated with DI. Data about other use of related medical
resources (consumption of needles and blood glucose tests,
and management of major hypoglycaemic episodes) has been
obtained from Spanish published literature. Costs calculations
refer to year 2007 and have been derived from Spanish databases
and published tariffs. RESULTS: Patients treated with ID require
65% more dose than those treated with GI, and suffer more
major hypoglycaemic events. In patients with DM2 management
with GI has lower total costs than DI, which allows savings up to
534.96€ per patient-year. Savings are related with costs of total
insulin, needles and blood glucose tests and also medical man-
agement required in case of major hypoglycaemic events. CON-
CLUSION: For patients with DM2 treatment with GI is an
efﬁcacious and safe therapeutic option compared with DI,
because GI is associated with lower annual total costs, and
allows saving up to 534.96€ per patient-year i.e. a 34% saving
per patient-year.
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OBJECTIVES: Pregnant women with diabetes report high rates
of neonatal mortality and morbidity. The costs of resulting inter-
ventions are potentially substantial. This study investigated
health outcomes and inpatient costs in pregnant women with
type 1 diabetes. METHODS: This analysis utilised a cohort of
302 pregnant women with type 1 diabetes, enrolled before 10
weeks gestation, with HbA1C  8% at conﬁrmation of preg-
nancy and for whom birth outcome was known. Subjects were
participating in a randomised study of basal-bolus insulin regi-
mens, with doses titrated in line with the American Diabetes
Association (ADA) guidelines. Outcomes recorded included
major maternal hypoglycaemia, neonatal hypoglycaemia, obstet-
ric complications, congenital malformations, foetal loss, birth
before 37 weeks gestation, birth weight >4000 g, and other
adverse events if life threatening or requiring hospitalisation.
Resulting inpatient costs were estimated from the perspective of
the UK National Health Service. RESULTS: The percentage of
subjects reporting major maternal hypoglycaemia was 29%,
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